United States was Perrigo’s largest region in fiscal 2025, bringing in $2.54B of $4.30B (59%).
| Geography | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | — | $2.92B | $2.65B | $2.54B | ||||||||||
| U.S | $2.87B | — | — | — | ||||||||||
| Unites States | — | — | — | — | ||||||||||
| Europe | $1.47B | $1.62B | $1.60B | $1.62B | ||||||||||
| Outside United States | — | — | — | — | ||||||||||
| All Other Countries | $107.30M | $116.30M | $119.50M | $96.70M | ||||||||||
| Ireland | $29.30M | $40.80M | $39.60M | $42.10M | ||||||||||
| Total | $4.48B | $4.70B | $4.41B | $4.30B |
Perrigo brought in $4.30B from its four regions in fiscal 2025, the year ended December 31, 2025. That was down 2.7% from $4.41B in fiscal 2024. United States was the largest at $2.54B (59.1%), ahead of Europe at $1.62B (37.6%) and All Other Countries at $96.70M (2.3%). The remaining region, Ireland, brought in $42.10M.
Compared with fiscal 2024, Europe grew fastest, up 0.7% to $1.62B, while All Other Countries fell the most, down 19.1% to $96.70M.
Perrigo stopped reporting U.S as a separate region after fiscal 2022, when it brought in $2.87B.
Branded Otc was Perrigo’s largest product and service line in fiscal 2017, bringing in $1.17B of $4.95B (24%).
| Product and Service | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 |
|---|---|---|---|---|---|
| Chc | — | — | — | — | |
| Branded Otc | — | — | $1.35B | $1.17B | |
| Generic Prescription Drugs | — | — | $1.04B | $969.70M | |
| Rx | $864.20M | — | — | — | |
| Infant Nutritionals | $374.80M | $200.20M | $427.00M | $413.90M | |
| Cough/Cold/Allergy/Sinus | — | $234.60M | $454.60M | $483.70M | |
| Cough/Cold | $477.60M | — | — | — | |
| Analgesics | $433.20M | $173.10M | $343.50M | $349.80M | |
| Other Chci | $331.10M | $167.10M | $303.00M | $317.00M | |
| Gastrointestinal | $398.40M | $195.80M | $335.40M | $340.00M | |
| Other Chca | $305.50M | $132.20M | $334.00M | $358.60M | |
| Cough, Cold, & Allergy | — | — | $348.20M | — | |
| Lifestyle | — | — | $300.20M | — | |
| Smoking Cessation | $236.80M | $147.50M | $308.50M | $297.20M | |
| Personal Care & Derma-Therapeutics | — | — | $269.10M | — | |
| Vitamins, Minerals & Dietary Supplements | — | — | $160.40M | $45.40M | |
| Vitamins, Minerals, & Dietary Supplements | $176.90M | — | — | — | |
| Animal Health | $178.00M | $62.30M | $143.70M | $141.30M | |
| Natural Health & Vitamins, Minerals And Dietary Supplements | — | — | $124.50M | — | |
| Anti-Parasite | — | — | $111.00M | — | |
| Active Pharmaceutical Ingredients | $137.60M | $45.10M | $78.50M | $55.60M | |
| Total | $3.91B | $1.36B | $6.43B | $4.95B |
Perrigo brought in $4.95B from its 12 product and service lines in fiscal 2017, the year ended December 31, 2017. Perrigo regrouped these lines after fiscal 2016, so the total does not compare directly with that year's $6.43B. Branded Otc was the largest at $1.17B (23.7%), ahead of Generic Prescription Drugs at $969.70M (19.6%) and Cough/Cold/Allergy/Sinus at $483.70M (9.8%). The other nine lines brought in $2.32B combined.
Compared with fiscal 2016, Other Chca grew fastest, up 7.4% to $358.60M, while Branded Otc fell the most, down 13.0% to $1.17B.
Perrigo began breaking out Branded Otc in fiscal 2016, Generic Prescription Drugs in fiscal 2016, Cough/Cold/Allergy/Sinus in fiscal 2015 and Vitamins, Minerals & Dietary Supplements in fiscal 2016. Perrigo stopped reporting Rx ($864.20M in fiscal 2014), Cough/Cold ($477.60M in fiscal 2014), Cough, Cold, & Allergy ($348.20M in fiscal 2016) and five others as separate lines.
Chci was Perrigo’s largest segment in fiscal 2017, bringing in $1.17B of $2.68B (44%).
| Statement Business Segments | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2015 | FY 2016 | FY 2017 |
|---|---|---|---|---|---|---|---|
| Rx Pharmaceuticals | — | $936.00M | — | — | $969.70M | ||
| Chci | $331.10M | $704.60M | $167.10M | $1.35B | $1.17B | ||
| Consumer Healthcare International | $331.10M | — | — | — | — | ||
| Rx | $864.20M | — | — | — | — | ||
| Chc | — | — | — | — | — | ||
| Consumer Healthcare | — | — | — | — | — | ||
| Chca | $477.60M | $455.60M | $234.60M | — | $483.70M | ||
| Nutritionals | — | — | — | — | — | ||
| Active Pharmaceutical Ingredients | — | — | — | — | — | ||
| Api | — | — | — | — | — | ||
| Other | — | $107.70M | $45.10M | — | $55.60M | ||
| All Other Segments | $137.60M | — | — | — | — | ||
| Pharaceutical & Medical Diagnostic Products | — | — | — | — | — | ||
| Total | $2.14B | $2.20B | $446.80M | $1.35B | $2.68B |
Perrigo brought in $2.68B from its four segments in fiscal 2017, the year ended December 31, 2017. That is less than the $4.95B it reports by product and service, so these segments do not cover all of its revenue. Chci was the largest at $1.17B (43.8%), ahead of Rx Pharmaceuticals at $969.70M (36.1%) and Chca at $483.70M (18.0%). The remaining segment, Other, brought in $55.60M.
Perrigo began breaking out Other in fiscal 2015, when it brought in $107.70M. Perrigo stopped reporting Rx ($864.20M in fiscal 2014), Consumer Healthcare International ($331.10M in fiscal 2014) and All Other Segments ($137.60M in fiscal 2014) as separate segments.
Perrigo (PRGO) reports its revenue by geography, by product and service and by statement business segments. In fiscal 2025, United States was its largest region, bringing in $2.54B (59.1% of the total), followed by Europe at $1.62B (37.6%).
United States was Perrigo's largest region in fiscal 2025, bringing in $2.54B, or 59.1% of the $4.30B total across its four regions.
Branded Otc was Perrigo's largest product and service line in fiscal 2017, bringing in $1.17B, or 23.7% of the $4.95B total across its 12 product and service lines.
Chci was Perrigo's largest segment in fiscal 2017, bringing in $1.17B, or 43.8% of the $2.68B total across its four segments.
Among Perrigo's regions that make up at least 2% of revenue, Europe grew fastest in fiscal 2025, up 0.7% from $1.60B to $1.62B.
Every figure comes from Perrigo's annual financial filings, as reported. Each line keeps the name Perrigo gives it, and years follow its fiscal calendar.
Perrigo's revenue by geography goes back to fiscal 2012, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.